Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 58 Novo Nordisk is the market leader in the USA within the modern and new-generation insulin segment USA insulin market by segment Device penetration - Novo Nordisk Modern insulin and new-generation insulin volume market shares in the USA Sanofi Eli Lilly Modern insulin penetration tMU Penetration CAGR volume¹: 2.2% 160 100% 60% CAGR value¹: 18.2% 140 50% 80% 120 Fast-acting 40% 100 60% 80 Premix 30% 60 40% 20% 40 Long-acting 20% 10% 20 0 0% 0% Aug 2013 Aug 2018 1 CAGR for 5-year period Source: IQVIA monthly MAT Aug, 2018 volume and value (DKK) figures changing diabetes Aug 2013 Source: IQVIA monthly MAT Aug, 2018 volume figures 41% 33% 27% Aug 2018 novo nordisk

View entire presentation